☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - September 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Denosumab (Prolia®) has been rejected for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - September 2018' by emailShare 'SMC Update - September 2018' on FacebookShare 'SMC Update - September 2018' on TwitterShare 'SMC Update - September 2018' on LinkedInShare 'SMC Update - September 2018' on reddit


No Comments to “SMC Update - September 2018”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.